PAVM trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes PAVM achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 24, 2026, PAVmed Inc. (PAVM) has a Wall Street consensus price target of N/A, based on estimates from 3 covering analysts. The company has a market capitalization of $14M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, PAVM trades at a trailing P/E of -0.4x. Analysts expect EPS to grow -39.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NVCRNovocure Ltd | $1.7B | $14.68 | $26.00 | +77.1% | Buy | — | 15 |
 INVAInnoviva, Inc. | $1.5B | $20.66 | $38.00 | +83.9% | Buy | 8.5x | 10 |
 MGRXMangoceuticals, Inc. | $4M | $0.23 | — | — | — | — | — |
 ATECAlphatec Holdings, Inc. | $1.7B | $11.11 | $16.22 | +46.0% | Buy | 34.0x | 20 |
 GKOSGlaukos Corporation | $10.6B | $178.88 | $192.90 | +7.8% | Buy | — | 25 |
 TMDXTransMedics Group, Inc. | $2.4B | $70.74 | $99.63 | +40.8% | Buy | 48.3x | 13 |
 PRCTPROCEPT BioRobotics Corporation | $1.1B | $19.96 | $23.00 | +15.2% | Buy | — | 16 |
 MDTMedtronic plc | $122.5B | $95.41 | $97.73 | +2.4% | Buy | 16.0x | 51 |
 BSXBoston Scientific Corporation | $67.9B | $45.69 | $59.55 | +30.3% | Buy | 14.1x | 44 |
 SYKStryker Corporation | $117.7B | $307.15 | $365.89 | +19.1% | Buy | 20.5x | 52 |
Quick answers to the most common questions about buying PAVM stock.
The consensus price target for PAVM is $N/A, close to the current price of $2.17 (N/A% implied move). Based on 3 analyst estimates, the stock appears fairly valued near current levels.
PAVM has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
PAVM's current price is $2.17 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $N/A for PAVM, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
PAVM is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PAVM stock forecast based on 3 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
PAVM appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PAVM analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.